KeypointsWe have assessed if GERD‐recommended treatment with PPI (dose and duration) can significantly reduce the signs and symptoms of LPR and comorbid CRS.Treating patients with LPR and comorbid CRS with omeprazole 20 mg OD for 8 weeks significantly reduced both subjective and objective signs and symptoms of LPR and comorbid CRS when compared to placebo.However in most patients (>75%) on active treatment, signs and symptoms were still present at the end of the trial suggesting the need to find the appropriate dose and duration of treatment..INTRODUCTIONChronic rhinosinusitis (CRS) is in the realm of scientific interest, as its aetiology and association with other respiratory and multimorbid disorders have not yet been clarified. It is a public health concern as between 10% and 30% of the adult population suffer from CRS. In patients with CRS, one should rule out or treat allergies, asthma or other underlying conditions as infections, inflammation associated with environmental factors, anatomic alterations or a combination of the mentioned. Latest literature proposes laryngopharyngeal reflux (LPR) as the underlying contributory factor for chronic inflammation in both upper and lower airways. The mechanism leading to airways mucous membrane damage is still not fully understood, but chemical injury induced by low
Clinical Otolaryngology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera